CXL therapy benefits patients with progressive keratoconus

Article

Collagen crosslinking (CXL) in patients with progressive keratoconus was found to be effective after 2 years in improving uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), topographic metrics, and most corneal higher-order aberrations, according to a study published in Cornea: The Journal of Cornea and External Disease. Researchers noted that there was a significant reduction in apical keratometry, which directly correlated with improvements in visual acuity

Collagen crosslinking (CXL) in patients with progressive keratoconus was found to be effective after 2 years in improving uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), topographic metrics, and most corneal higher-order aberrations, according to a study published in Cornea: The Journal of Cornea and External Disease. Researchers noted that there was a significant reduction in apical keratometry, which directly correlated with improvements in visual acuity.

For this prospective case series, researchers included 42 eyes from 32 patients who had progressive keratoconus treated with CXL. Main outcomes measured at baseline, 6 months, 12 months, and 24 months after treatment were UDVA, CDVA, refractive changes, topographic data, and corneal aberrations.

At 2 years post-CXL treatment, UDVA, CDVA, and spherical equivalents all improved significantly (P P P P P

Aberration analyses showed significant reductions in coma (P = 0.016), trefoil (P = 0.018), secondary astigmatism (P P = 0.031), secondary coma (P P = 0.001). Corneal higher-order aberrations, except quatrefoil, all showed significant correlation with postoperative CDVA, with the highest occurring with coma (rho = 0.703; P P = 0.001), and total HOA (rho = 0.487; P = 0.001.

Higher-order aberrations, however, were not statistically associated with improved visual acuity. Reductions in apical keratometry was the only post-treatment variable associated with improvement in CDVA (rho = 0.319; P = 0.042).

For view a copy of the abstract of this study, click here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.